Categories
Health

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is  a   biotech which has been effective vigilantly but unsuccessfully to produce a single therapy, variously referred to as Pro 140, leronlimab, along with Vyrologix.

In development of this treatment, CytoDyn has cast its net wide and far both geographically and in terminology of possible indications.

CytoDyn’s inventories of leronlimab are actually building up, whether they will actually be used is an open question.

While CYDY  happens to be dawdling, promote opportunities for leronlimab as being a combination treatment in the healing of multi-drug-resistant HIV happen to be closing.

I’m creating my fifteenth CytoDyn (OTCQB:CYDY) article on FintechZoom to celebrate the sale made of my past several shares. The first CytoDyn article of mine, “CytoDyn: What to be able to Do When It’s Too Good In order to Be True?”, set away all of the following prediction:

Instead I expect it to be a serial disappointer. CEO Pourhassan presented such a very marketing image in the Uptick Newswire interview which I came away with a bad impression of the company.

Irony of irony, the bad opinion of mine of the company has grown steadily, although the disappointment hasn’t been financial. 2 many years ago CytoDyn was trading <$1.00. On 2/19/20 as I write, it trades during $5.26; my closing transaction was on 2/11/21 > $6.00.

What manner of stock  is this that delivers a > 6 bagger yet still disappoints? Therein lies the story; let me explain.

CytoDyn acquired its much-storied treatment (which I shall refer to as leronlimab) back during 2012, announced as follows:

CytoDyn Inc…. has completed the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) focusing on the CCR5 receptor for the treatment and reduction of HIV, from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is actually a late Stage II clinical growth mAb with demonstrated anti-viral activity of HIV- infected subjects. Today’s transaction of $3.5 huge number of transfers ownership of this technology and also connected intellectual property from Progenics to CytoDyn, and also approximately twenty five million mg of bulk drug substance…. milestone payments upon commencement of a phase III clinical trial ($1.5 million) and also the very first new drug application approval ($5 million), as well as royalty payments of 5 % of net sales after commercialization.

Since that time, CytoDyn’s leading nous, Nader Pourhassan [NP] has transformed this inauspicious acquisition into a springboard for CytoDyn to acquire a market place cap > $3.5 billion. It has done so in exclusive reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

As opposed to having a pipeline with multiple indications and numerous therapies, it’s this single therapies and a “broad pipeline of indications” as it places it. I call certain pipelines, “pipedots.” In CytoDyn’s case it touts its leronlimab as a likely beneficial therapy in dozens of indications.

The opening banner of its on the website of its (below) shows an active business with diverse interests albeit focused on leronlimab, several disease types, multiple publications and multiple presentations.

Might all this be smoke cigarettes and mirrors? That is a question I have been asking myself through the very start of my interest in this company. Judging by way of the multiples of thousands of diverse remarks on listings accessible via Seeking Alpha’s CytoDyn Summary webpage, I am a lot from alone in this question.

CytoDyn is a classic battleground, or perhaps some could say cult inventory. Its adherents are fiercely shielding of its prospects, quick to label some bad opinions as scurrilous short-mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Leave a Reply

Your email address will not be published. Required fields are marked *